Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (TWST) is a leader in synthetic DNA production, utilizing a proprietary semiconductor-based platform to drive innovations across biotechnology and healthcare. This page provides investors and industry professionals with timely, accurate updates on TWST's strategic developments and operational milestones.
Access consolidated press releases and news covering earnings announcements, product launches, research breakthroughs, and partnerships. Our curated updates ensure you stay informed about TWST's advancements in gene synthesis, high-throughput manufacturing, and applications in precision medicine.
Key content includes quarterly financial results, regulatory filings, technology patents, and collaborations with academic or industry partners. All materials are sourced directly from verified company communications to maintain factual integrity.
Bookmark this page for streamlined access to TWST's evolving role in synthetic biology. Check regularly for critical updates impacting market positioning and technological leadership in DNA synthesis.
Twist Bioscience (NASDAQ: TWST) granted a total of 139,569 equity awards as inducements to 41 newly hired employees: 91,441 restricted stock units (RSUs) and up to 48,128 performance stock units (PSUs). RSU vesting schedules vary by employee, with portions vesting over 48 months — either 25% at the one-year anniversary then 1/16 quarterly, or 1/16 quarterly from the Vesting Commencement Date — subject to continued service.
Up to 48,128 PSUs vest based on performance metrics set by the Compensation Committee, to be achieved no later than the end of the 2027 fiscal year, with payout range from 50% to 140% of target, subject to service-based vesting conditions.
Twist Bioscience (NASDAQ: TWST) will report fiscal 2025 fourth quarter and full year results for the period ended September 30, 2025 on Friday, November 14, 2025 before market open. A conference call and live audio webcast for analysts and investors is scheduled for 8:00 AM ET the same day to review results and provide a business update.
The press release with financial results will be posted in the company Investor Relations section at www.twistbioscience.com prior to the call. Telephone participants must register on the Investor Relations site to receive a dial-in number and unique PIN. Attendees are encouraged to dial in 15 minutes early. A webcast replay will be available for two weeks.
Twist Bioscience (NASDAQ: TWST) and Element Biosciences launched the Trinity Freestyle Fast Hybridization workflow for Element’s AVITI and AVITI24 sequencing platforms on October 6, 2025. The end-to-end solution enables sample-to-sequencer runs in as little as five hours and uses a rapid 1-hour hybridization with on-flow cell enrichment to remove binding, wash, amplification and pooling steps. Under an expanded agreement, Twist gains exclusive access to the Trinity Freestyle workflow for use with Twist’s library prep kits, including Enzymatic Fragmentation Kit 2.0 and FlexPrep UHT. The integration aims to provide compatibility with P5/P7-adapted libraries and Twist unique dual indexes, with expanded support subject to further validation.
Twist Bioscience (NASDAQ: TWST) on October 2, 2025 announced co-authorship of a peer‑reviewed paper in Science titled “Strengthening nucleic acid biosecurity screening against generative protein design tools.”
The study, led by Microsoft with industry and scientific partners including the International Gene Synthesis Consortium, ran a red‑teaming exercise showing some AI‑designed protein variants could evade standard biosecurity screening. Twist and collaborators used the results to develop patches and new screening strategies to improve detection of engineered sequences. The paper emphasizes iterative improvement, cross‑industry collaboration, and foresight to mitigate AI‑related biosecurity risks while noting the tested sequences were digital and their pathogenicity if manufactured is unknown.
Twist Bioscience (NASDAQ: TWST), a mid-cap biotech company, has announced upcoming presentations at two major healthcare conferences. CEO and co-founder Emily M. Leproust, Ph.D. will present at the Baird 2025 Global Healthcare Conference on September 9, 2025, at 9:40 am ET in New York City.
Additionally, the company will participate in one-on-one meetings at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025. Both presentations will be accessible via webcast through the company's investor relations website, with replays available for 30 days after the events.
Twist Bioscience (NASDAQ: TWST) has announced a collaboration with Synthetic Design Lab (SDL) to support the development of novel antibody-drug conjugates for cancer treatment. The partnership leverages Twist's high-throughput expertise and proprietary tools to advance SDL's SYNTHBODY platform.
The collaboration combines Twist's capabilities in novel binder discovery services and high-throughput screening with SDL's innovative approach to developing next-generation therapeutics. This partnership aims to enhance the development of advanced therapeutic solutions for various cancer types.
Twist Bioscience (NASDAQ: TWST) has launched its new Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a research-use-only solution for tumor genomic profiling. The customizable panel covers 562 genes across major tumor types and can detect various genomic alterations including base substitutions, insertions, deletions, copy number variations, and gene rearrangements.
The panel also measures tumor mutational burden (TMB) and microsatellite instability (MSI), offering a flexible workflow compatible with multiple sequencing platforms. Designed for regional clinical labs, academic medical centers, and biopharma partners, the solution aims to provide a cost-effective and efficient alternative to existing CGP products and smaller panels.
Twist Bioscience (NASDAQ: TWST) has appointed Trynka Shineman Blake to its board of directors and audit committee. Ms. Shineman Blake, former CEO of Vistaprint, brings nearly three decades of experience in corporate governance, customer experience, digital transformation, and global marketing.
During her tenure at Vistaprint, she played a crucial role in scaling the business from under $100 million to over $1 billion in revenue. Her appointment comes at a strategic time as Twist advances toward adjusted EBITDA breakeven while maintaining focus on innovative solutions.
Twist Bioscience (NASDAQ: TWST) has announced its financial results for the third quarter of fiscal 2025, ended June 30, 2025. CEO Emily M. Leproust highlighted the company's strong balance sheet and disciplined cost management approach that supports their business execution.
The company will host a conference call and webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss the quarterly results. Interested participants must pre-register through the company's website to receive dial-in details.
Twist Bioscience (NASDAQ: TWST) has launched a new humanized transgenic (HuTg) mouse model to enhance its antibody discovery services. The new model offers a fee-for-service approach, eliminating the need for traditional licensing negotiations with providers.
The HuTg platform can be integrated with Twist's existing DiversimAb mouse model and B cell screening platforms, enabling researchers to generate human antibody candidates more efficiently. The technology accelerates lead discovery and optimization, reducing the timeline from months to weeks for identifying fully human hits.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
